Status:
COMPLETED
Three Different Transdermal Doses of Rotigotine in Subjects With Idiopathic Restless Leg Syndrome
Lead Sponsor:
UCB Pharma
Conditions:
Restless Legs Syndrome
Eligibility:
All Genders
18-75 years
Phase:
PHASE3
Brief Summary
The primary objective of this trial is to demonstrate that rotigotine (SPM 936) is efficacious in subjects with idiopathic restless leg syndrome (RLS). Additional objectives are to investigate the saf...
Eligibility Criteria
Inclusion
- Idiopathic RLS
Exclusion
- History of sleep disturbances
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2006
Estimated Enrollment :
549 Patients enrolled
Trial Details
Trial ID
NCT00136045
Start Date
May 1 2005
End Date
August 1 2006
Last Update
September 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Schwarz
Monheim, Germany